Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Equity (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Return on Equity for 2 consecutive years, with 1.64% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 67.0% to 1.64% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.64% through Dec 2025, down 67.0% year-over-year, with the annual reading at 1.05% for FY2025, N/A changed from the prior year.
  • Return on Equity hit 1.64% in Q4 2025 for Prelude Therapeutics, up from 1.8% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.97% in Q4 2024 to a low of 1.8% in Q3 2025.